Navigation Links
Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution
Date:1/3/2008

BEDFORD, Ohio, Jan. 3 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories Inc., announced the acquisition of CAFCIT(R) (caffeine citrate) Injection and CAFCIT(R) (caffeine citrate) Oral Solution from Mead Johnson & Company. Bedford Laboratories is now the reference listed drug holder. CAFCIT(R) (caffeine citrate) is indicated for the short term treatment of apnea in premature infants between 28 and <33 weeks gestational age.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )

"The acquisition of CAFCIT(R) demonstrates our continued commitment to build the most comprehensive and cost effective line of injectable products in the pharmaceutical industry. We are proud to offer a branded product at a generic price," said David Gaugh, Vice President and General Manager of Bedford Laboratories.

Bedford Laboratories will supply latex free CAFCIT(R) (caffeine citrate) Injection and CAFCIT(R) (caffeine citrate) Oral Solution as a sterile liquid in the following presentations:

-- Injection: 60 mg/3 mL single-use vials individually boxed

-- Oral Solution: 60 mg/3 mL single-use vials, 10 vials per child-

resistant container

Prescribing information is available upon request from the Bedford Laboratories' professional services department, (800) 521-5169, or from the company's web site, http://www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and international markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim <
'/>"/>

SOURCE Bedford Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Alma Lasers Announces Proposed Initial Public Offering
2. Smart Balance Announces Conversion of Convertible Preferred Stock
3. IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives
4. MQ Associates, Inc. Announces Cash Tender Offer for 121/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Related Consent Solicitation
5. Heska Announces Amended Agreement With AgriLabs
6. Versus Technology Announces Fourth Quarter Results
7. FASgen Announces New Research Discoveries in Lung Cancer
8. Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator
9. KV Pharmaceutical Company Announces NYSE Listing Extension
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
11. Transition Therapeutics Announces Appointment of Vice-President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... , ... August 01, 2015 , ... On Tuesday, July ... , who are thought to have been behind the attack on Anthem Inc. which ... were zero day exploits, watering hole attacks and spear phishing campaigns. , ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... High Times magazine. What are the STASH awards? The Significant Technological Achievements ... by the cannabis-cultivation community as well as tried-and-true products that have stood the ...
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... Ticket ... which is currently going on in Chicago at Grant Park. The festival will ... corner of North America to Chicago for the annual Lollapalooza. This unique and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the ... new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round ... MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands of ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... HI---As school buses drive down the gravel roads in Dunn ... clouds of dust left in their wake contain such high ... the air every day are at an increased risk of ... the lungs, new research shows. Erionite is a natural mineral ...
... Laws, a second-year student in the master of social work ... Social Work (GCSW), is one of five outstanding graduate students ... for Mental Health. "Ana Luisa Laws clearly is ... ever had in the University of Houston Graduate College of ...
... News) -- Children and teens with abnormal development of the ... sports, such as soccer and basketball, are at greater risk ... Swiss researchers explained that deformities of the top of ... reduced rotation and pain during movement among young competitive athletes. ...
... Is it possible to predict whether someone is likely ... A new study by researchers at Wake Forest Baptist ... people, the first heart attack is more likely to be ... of the Epidemiological Cardiology Research Center (EPICARE) at Wake Forest ...
... a picture of many trees, young people will tend to say: ... likely we are to notice a single tree before seeing the ... the bigger picture is slower in older people. In a new ... researchers have found that these age-related changes are correlated with a ...
... SUNDAY, July 24 (HealthDay News) -- For patients suffering chest ... therapy may result in severe bleeding without reducing the risk ... A trial evaluating the combination treatment was halted early when ... became apparent. "It is very clear there is an ...
Cached Medicine News:Health News:New study finds cancer-causing mineral in US road gravel 2Health News:New study finds cancer-causing mineral in US road gravel 3Health News:University of Houston student awarded Hogg Foundation Scholarship 2Health News:Predictors of dying suddenly versus surviving heart attack identified 2Health News:Older people find it harder to see the wood for the trees 2Health News:Anti-Clotting Drug May Cause Severe Bleeding With No Benefit 2Health News:Anti-Clotting Drug May Cause Severe Bleeding With No Benefit 3
(Date:7/30/2015)... IRVINE, Calif. , July 30, 2015 /PRNewswire/ ... Novartis /Alcon executives have recently contacted the Company ... will begin as early as Monday, August 3, ... been quoted as saying that the coming electronic ... billions of dollars over the next several years.  ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
(Date:7/30/2015)... Ohio , July 30, 2015  Cleveland Clinic ... OMTEC® 2015 keynote address last month that industry is ... in order to gain the efficiencies—and develop the transformational ... Dr. Barsoum,s comments were preceded by Doug ... entrepreneur and OMTEC moderator, who stressed that industry must ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... Materia, Inc., a,catalyst technology company, announced today ... Co., Ltd., a leading Japanese,pharmaceutical company, for ... license agreement provides rights to discover,develop, and ... Company's catalysts and associated intellectual property., Metathesis ...
... Calif.--(BUSINESS WIRE)--Jun 25, 2007 - VIVUS, Inc.,(NASDAQ: ... and commercialization of novel therapeutic products,announced that ... Diabetic Patients Treated with Phentermine and Topiramate:,Outcomes ... published in the,American Diabetes Association 2007 Scientific ...
Cached Medicine Technology:Materia Licenses Metathesis Catalyst Platform to Eisai 2VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions 2VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions 3
The K-ASSAY ITA Lyophilized Multi-Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assays for the li...
... K-ASSAY ASO / RF / ... to be used as a ... concentration for monitoring the performance ... Rheumatoid Factor (RF), and C-Reactive ...
... The Directigen EZ Flu A+B test ... direct and qualitative detection of influenza A ... and throat swabs of symptomatic patients. The ... differentiated test, such that influenza A viral ...
... The InVance Male Sling System is an ... mild to moderate stress urinary incontinence in ... solution for men who are not candidates ... limited manual dexterity, limited mental capacity or ...
Medicine Products: